PRO 140

Drug Profile

PRO 140

Alternative Names: Humanized monoclonal antibody to CCR5; PA-14; PRO-140

Latest Information Update: 24 Mar 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Progenics Pharmaceuticals
  • Developer CytoDyn; Progenics Pharmaceuticals; The Scripps Research Institute
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action CCR5 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III HIV infections
  • Phase II/III HIV-1 infections
  • Phase II Graft-versus-host disease

Most Recent Events

  • 01 Mar 2017 Drexel University and National Institute on Drug Abuse withdraw a phase II trial prior to enrolment in HIV-1-infections (Adjunctive treatment) in USA before March 2017 (NCT02438345)
  • 13 Feb 2017 Interim efficacy, adverse events and pharmacokinetics data from a phase IIb extension trial in HIV-1-infections presented at the 24th Conference on Retroviruses and Opportunistic Infections (CROI-2017)
  • 01 Feb 2017 CytoDyn withdraws a phase II trial prior to enrollment due to lack of enrollment in HIV-1-infections (Adjunctive treatment) in USA (SC, Injection) (NCT01272258)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top